Colourant specialist Sparxell gets key fashion innovation recognition
The UK company has been named among the prestigious 'ChangeNow Change 100' winners for 2025, joining 'a definitive list of the top sustainability start-ups to watch this year'.
And during the recent ChangeNow summit in Paris, the company was additionally awarded the jury's 'Coups de Cœur' recognition in the fashion category, highlighting its game-changing potential to transform the fashion industry'.
Sparxell, a University of Cambridge spin-out and 'developer of the world's first high-performance, plant-based colourant technology', joins an elite group 'demonstrating exceptional impact potential, scalability, and business viability while creatively rethinking industry standards'.
It said this latest achievement reinforces its 'growing momentum as it transforms the $48 billion global colourants market with its revolutionary 100% plant-based, high-performance biodegradable colour platform'.
Dr Benjamin Droguet, founder and CEO of Sparxell said the two recognitions 'validate our mission to revolutionise how industries approach colour.
'This comes at a pivotal moment as we scale our technology to transform how the entire fashion industry approaches colour. Through this innovation, we're not just creating sustainable products - we're helping shape a world where beautiful, high-performance materials work in harmony with nature rather than against it.'
This recognition comes as Sparxell recently secured a €1.9 million grant from the European Innovation Council (EIC), adding to investments from the L'Oréal -backed Circular Innovation Fund and support from Innovate UK.
It has also established partnerships with luxury brands under LVMH's La Maison des Startups.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
LeMonde
3 days ago
- LeMonde
Trump gambles with reindustrializing the US
Attracting foreign investment to reindustrialize the US has been the main objective of Donald Trump's tariff policy. "Remember the army of millions and millions of human beings screwing in little screws to make iPhones? That kind of thing is going to come to America," promised US Secretary of Commerce Howard Lutnick on April 6, just days after Trump announced so-called "reciprocal" tariffs on April 2. The agreement unveiled on Sunday, July 27, with the European Union includes an additional $600 billion in investments to be made in the US. A few days earlier, Japan committed to invest $550 billion in the US as part of its agreement signed with Washington. These commitments, however, remain vague – both in terms of the time frame and the sectors involved. In recent weeks, several major European groups have announced plans to build factories in the US, raising concerns over reduced activities in Europe and even an increase in offshoring to the US. On July 24, Bernard Arnault, the founder and CEO of the luxury group LVMH, announced that Louis Vuitton would open a fourth manufacturing site across the Atlantic. "For our American customers, buying a Louis Vuitton product 'made in USA' poses (…) no problem at all," Arnault argued in the French newspaper Le Figaro on July 24.
Fashion Network
4 days ago
- Fashion Network
Luxury scent supplier dsm-firmenich lowers 2025 target
Dsm-firmenich, a leading supplier of fragrance ingredients to luxury houses such as LVMH and Kering, has narrowed its 2025 profit forecast, pointing to persistent foreign exchange volatility as a key challenge. The Swiss-Dutch group, known for its role in the global beauty and fragrance supply chain, now expects adjusted EBITDA to reach €2.4 billion ($2.74 billion), down from a previous estimate of at least €2.4 billion. 'In the underlying core business, nothing has changed, but FX — obviously, we can't control,' CEO Dimitri de Vreeze told Reuters, adding that he sees continued uncertainty in the second half. Dsm-firmenich, whose products are used in perfumes made by French luxury groups LVMH and Kering, reported adjusted core profit of €610 million for the first half. That beat analysts' average forecast of €513 million, based on a company-compiled consensus. 'It's like a duck that's nicely floating, but there's a lot of hard work underneath to keep it moving. That you don't see. But here we see a relatively good duck in good order for the first half, and we're confident for the second half,' the CEO told Reuters. In February, the company sold its stake in a joint enzymes venture to Danish group Novonesis for €1.5 billion as part of a strategic revamp aimed at sharpening its focus on core businesses such as perfumes and flavors. Last year, it announced plans to carve out its animal health and nutrition unit by the end of 2025 — a move expected to reduce exposure to earnings volatility in the vitamins segment. The unit reported a 293% year-on-year adjusted EBITDA increase to €342 million in the first half, supported by temporary vitamin price effects.
Fashion Network
4 days ago
- Fashion Network
Luxury scent supplier dsm-firmenich lowers 2025 target
Dsm-firmenich, a leading supplier of fragrance ingredients to luxury houses such as LVMH and Kering, has narrowed its 2025 profit forecast, pointing to persistent foreign exchange volatility as a key challenge. The Swiss-Dutch group, known for its role in the global beauty and fragrance supply chain, now expects adjusted EBITDA to reach €2.4 billion ($2.74 billion), down from a previous estimate of at least €2.4 billion. 'In the underlying core business, nothing has changed, but FX — obviously, we can't control,' CEO Dimitri de Vreeze told Reuters, adding that he sees continued uncertainty in the second half. Dsm-firmenich, whose products are used in perfumes made by French luxury groups LVMH and Kering, reported adjusted core profit of €610 million for the first half. That beat analysts' average forecast of €513 million, based on a company-compiled consensus. 'It's like a duck that's nicely floating, but there's a lot of hard work underneath to keep it moving. That you don't see. But here we see a relatively good duck in good order for the first half, and we're confident for the second half,' the CEO told Reuters. In February, the company sold its stake in a joint enzymes venture to Danish group Novonesis for €1.5 billion as part of a strategic revamp aimed at sharpening its focus on core businesses such as perfumes and flavors. Last year, it announced plans to carve out its animal health and nutrition unit by the end of 2025 — a move expected to reduce exposure to earnings volatility in the vitamins segment. The unit reported a 293% year-on-year adjusted EBITDA increase to €342 million in the first half, supported by temporary vitamin price effects. ($1 = €0.8744)
